Purchasers or acquirers of Hims & Hers Health securities between Aug. 4, 2025, and July 29, 2026, inclusive, have until Nov. 2, 2026, to seek appointment as lead plaintiff in a proposed securities class action. The case, Velanki v. Hims & Hers Health, Inc., No. 26-cv-09313, is pending in the Northern District of California and alleges that Hims & Hers and certain senior executives violated the Securities Exchange Act of 1934. The allegations concern the sharing of consumers’ health information with third-party advertising platforms, billing for prescriptions shortly after intake forms were submitted, and statements that allegedly misrepresented the company’s business, operations and prospects. The complaint says the conduct exposed Hims & Hers to regulatory scrutiny and potential fees and penalties. It cites an alleged July 29, 2026, Federal Trade Commission lawsuit concerning privacy, billing and cancellation practices, including data sharing with Meta Platforms and Snap. Hims & Hers shares declined nearly 15% on the news, according to the complaint. Robbins Geller Rudman & Dowd said investors do not need to serve as lead plaintiff to participate in any potential recovery.